Please assess the completion status of the following clinical trial:

Trial Title: Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with histologically proven, core-biopsied, invasive breast cancer of any clinical and/or radiological T-stage (except for T4d)~* Age 18-70 years~* WHO performance status ≤ 2~* No prior or current neoplasm except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix~* No distant disease / secondary carcinoma judged clinically and at least by chest X-ray, liver sonography, and bone scan upon randomization~* No medical and/or cardiologic contraindication to receive an anthracycline- and taxane-containing chemotherapy regimen. Normal cardiac function must be confirmed by LVEF (echocardiography or Muga scan). The result must be above 50% or above the institution's ULN~* Results of the following assessments at the time of randomization must be available:~  1. chest wall CT, abdomen CT, bilateral mammography: within 4 weeks before enrolment;~ 2. laboratory requirements: within 2 weeks before enrolment~ 3. hematology: neutrophils ≥ 4.0 x 109/l, platelets ≥ 150 x 109/l, haemoglobin ≥ 13 g/dl~ 4. hepatic function: total bilirubin \< 1 x ULN, ASAT (SGOT) and ALAT (SGPT) \< 1x ULN, alkaline phosphatase \< 1 x ULN. In case of abnormal values, liver function tests have to be repeated within 3 days before study treatment.~ 5. renal function: creatinine ≤ 1 x ULN,~ 6. histology, grading, hormone receptor status, HER-2/neu status~* Signed and dated informed consent before the start of specific protocol procedures~* Negative pregnancy test in the presence of childbearing potential~Exclusion Criteria:~* Stage T4d / inflammatory breast cancer~* Pregnant or lactating patients; patients of childbearing potential must implement adequate contraceptive measures during study participation~* Pre-existing motor or sensory neurotoxicity of a severity ≥ WHO grade 2~* Preoperative local treatment for breast cancer (i.e. incomplete surgery, radiotherapy)~* Prior or concomitant systemic antitumor therapy~* Other serious illness or medical condition~  1. congestive heart failure or unstable angina pectoris, even if medically controlled.~     Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrythmias~ 2. history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent~ 3. active uncontrolled infection~ 4. unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of corticosteroids~* Concurrent treatment with corticosteroids except as use for the prophylactic regimen, inhalational use, treatment of acute hypersensitivity reactions, treatment of nausea/vomiting or chronic treatment (initiated \> 6 months prior to study entry) at low dose (≤ 20 mg methylprednisolone or equivalent)~* Known hypersensitivity against taxanes and/or epirubicin and/or fluorouracil/capecitabine~* Known dihydropyrimidine-dehydrogenase (DPD) deficit~* Treatment with an investigational drug within 30 days prior to study entry~* Legally incapacitated and/or other circumstances which make it unfeasible for the subject to understand the nature, meaning and consequences of the clinical study~* Concurrent psychiatric illness according to ICD (alcohol addiction) at the time of study entry

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (experimental group) (Type: ACTIVE_COMPARATOR): Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
- B (control group) (Type: ACTIVE_COMPARATOR): Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease

Based on this trial design, predict the completion outcome and termination type (if applicable).